Dublin, May 29, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Duchenne Muscular Dystrophy Therapeutics Market By Drug, By Therapeutic Approach Clinical Trial Assessment & Pipeline Analysis Outlook 2022" report to their offering. The Duchenne Muscular Dystrophy Therapeutics market has very few marketed products, such as Emflaza, Translarna, and EXONDYS 51.
The market is majorly in the research phase, from which most of its revenue is generated. Therefore, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the Duchenne Muscular Dystrophy market, such as phases, geographies, etc. The report also provides the sales of major marketed Duchenne Muscular Dystrophy products, and the list of the products in clinical/pre-clinical research along with their clinical phases. The report provides a detailed analysis of the current and future market scenario of the global Duchenne Muscular Dystrophy Therapeutics market. The author in its report, further covers insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Duchenne Muscular Dystrophy Therapeutics market. The report also provides insights regarding the strategies adopted by the players from 2015 to 2017 for enhancing their market share. The segmentation of Duchenne Muscular Dystrophy Therapeutics market has been done on the basis of different therapeutic approaches and geographical regions. Primarily, the Duchenne Muscular Dystrophy Therapeutics market is dominated by mutation suppression and exon skipping approach, with several companies and academic institutions focusing on potential for each of these treatments. Based on the geography, the market is divided into three regions, namely - North America, Europe, and Asia Pacific. There are several treatments for DMD that are approved or under review in the European Union or are expected to be under review by regulatory agencies in the near future. This is a major reason for the dominant position of Europe in the Duchenne Muscular Dystrophy market. The later part of the report discusses some of the prominent players in the global Duchenne Muscular Dystrophy Therapeutics market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Duchenne Muscular Dystrophy (DMD): An Overview 4. Market Dynamics 4.1 Market Drivers 4.1.1 Growing Prevalence of Duchenne Muscular Dystrophy 4.1.2 Rising Acceptance of Duchenne Muscular Dystrophy Drugs in the Market 4.1.3 Increasing Funding Support & Grants 4.1.4 Increasing Awareness 4.1.5 Robust and Opportunistic Pipeline 4.2 Restraints 4.2.1 Pediatric Neuromuscular Disease 4.2.2 Lack of Disease History and Research Participants 4.2.3 Diagnosis and Management of Duchenne Muscular Dystrophy in Developing Countries 4.2.4 High Cost of Care 4.3 Opportunities 4.3.1 PPMO: Next Generation Antisense Platform 4.3.2 Growing Market Opportunity in Emerging Countries 4.3.3 High Unmet Need for an Effective Disease Modifying Therapy 4.3.4 Gene Therapy 4.3.5 Utrophin Modulation 4.3.6 Biomarkers for Duchenne Muscular Dystophy 5. Global Duchenne Muscular Dystrophy Therapeutics Market Outlook 2022 6. Approved Drugs 6.1 Emflaza (deflazacort) 6.2 EXONDYS 51 (eteplirsen) 6.3 Translarna (ataluren) 7. Market Segmentation by Therapeutic Approach 7.1 Mutation Suppression 7.2 Steroid Therapy 7.3 Exon Skipping Therapy 8. Market Segmentation by Geography 8.1 Europe 8.2 North America 8.3 Asia Pacific 9. Clinical Trial Assessment & Pipeline Analysis 9.1 Clinical Trials 9.1.1 By Geography 9.1.2 By Clinical Trial Phase 9.1.3 By Key Players 9.2 Pipeline Analysis 10. Industry Trends and Developments 10.1 Administration of Corticosteroids 10.2 Collaboration amongst Industry Players and Non-Industry Participants 10.3 Exon-Skipping Technology Crowding the DMD Therapeutics Industry 10.4 Carrier Screening for Duchenne Muscular Dystrophy 11. Strategic Alliances 12. Competitive Landscape 13. Key Player Analysis 13.1 Marathon Pharmaceuticals, LLC 13.2 PTC Therapeutics, Inc. 13.3 Sarepta Therapeutics, Inc. 13.4 ITALFARMACO S.p.A. 13.5 Santhera Pharmaceuticals 13.6 Bristol-Myers Squibb 13.7 ReveraGen BioPharma, Inc. 13.8 Catabasis Pharmaceuticals, Inc. 13.9 FibroGen, Inc. 13.10 NS Pharma, Inc. 13.11 Pfizer 13.12 Summit Therapeutics plc 13.13 Taiho Pharmaceutical Co., Ltd. (Division of Otsuka Holdings Co. Ltd.) 14. Future Outlook For more information about this report visit http://www.researchandmarkets.com/research/72...l_duchenne
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Central Nervous System Drugs , Clinical Trials, Musculoskeletal Disorders Drugs
